For example, inhibition of MK2 by MK2.III was shown to sensitize p53 mutated pancreatic cancer cells (Panc1 and MIA PaCa-2) and osteosarcoma (U2OS) to cisplatin [44], and, in contrast, protect cancer cells from gemcitabine [44–46]. This evidence concerns the gene MAPKAPK2 and pancreatic neoplasm.